Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib, which could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback